NASDAQ · Diagnostics & Research · USD

ENDRA Life Sciences Inc. Common Stock (NDRA) Stock Analysis

ENDRA Life Sciences Inc. Common Stock (NDRA) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NDRA

$4.68

+$0.21 (+4.70%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NDRA with… →

NDRA Key Statistics

As of Oct 21, 2026

Trading

Open: $4.48
Previous Close: $4.47
Day's Range: 4.48–4.79
52-Week Range: 2.96–6.95
Volume: 17.38K
Beta: −0.08

Valuation

Market Cap: $7.02M
P/E Ratio: unprofitable
EPS (ttm): −6.26

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$7.03M
Shares Outstanding: 1.50M
1-Year Return: −23.65%

Dividend and dates

Avg Volume: 31.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NDRA closed at $4.68, −23.65% over 1 year.

ENDRA Life Sciences Inc. Common Stock (NDRA) has a market capitalization of $7.02M.

In fiscal 2025, NDRA reported revenue of $0.00.

NDRA Stock Return by Calendar Year

ENDRA Life Sciences Inc. Common Stock (NDRA) return since Jun 2017: what $10,000 became

1 year: $10,000 $7,635; −23.65%
5 years: $10,000 $0.77; −99.99%
Since Jun 2017: $10,000 $0.34; −99.997%

If you had invested $10,000 in ENDRA Life Sciences Inc. Common Stock (NDRA) at the close on June 30, 2017, the earliest close on record here, it would have been worth $0.34 at the close on October 21, 2026: −99.997% in total, −66.86% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+24.62%−99.83%+3.31%

2017*201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+3.31%
2025	−27.64%
2024	−99.83%
2023	−47.91%
2022	−70.59%
2021	−7.73%
2020	−55.36%
2019	+12.00%
2018	−69.14%
2017 (partial year)	+24.62%

As of October 21, 2026.

NDRA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$7.03M	—
2024	$0.00	−$11.51M	—
2023	$0.00	−$10.06M	—
2022	$0.00	−$13.18M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$5.76M	−$7.03M	—
2024	$0.00	—	−$10.82M	−$11.51M	—
2023	$0.00	—	−$10.52M	−$10.06M	—
2022	$0.00	—	−$13.16M	−$13.18M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

ENDRA Life Sciences Inc. Common Stock (NDRA) is capitalised at $7.02M on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 9.

The most recent close on file for NDRA is $4.68, dated October 21, 2026. That is +$0.21 (+4.70%) against the previous close. The 52-week range on file runs from $2.96 to $6.95. The latest close sits 58.11% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $7.03M. Earnings per share on a trailing basis come to −6.26.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −23.65%. Measured over 5 years, that is −84.95% a year compounded. Beta against the wider market is reported at −0.08. Daily returns over the trailing 9 years annualize to a volatility of 129.52%.

Growth & Income

No dividend is on file for NDRA.

Across the complete calendar years on file, 2019 returned +12.00% and 2024 returned −99.83%. Of the 8 complete calendar years on file, 1 finished higher. So far in 2026 the total return is +3.31%.

Peer Comparison

ENDRA Life Sciences Inc. Common Stock (NDRA) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ENDRA Life Sciences Inc. Common Stock	NDRA	$7.02M	—
Thermo Fisher Scientific Inc.	TMO	$256.61B	37.4
Danaher Corporation	DHR	$164.40B	41.7
Natera, Inc.	NTRA	$59.59B	—

The Diagnostics & Research industry average P/E ratio is 37.6x. ENDRA Life Sciences Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

DHR

Danaher Corporation

$164.40B

NTRA

Natera, Inc.

$59.59B

Agilent Technologies, Inc.

$50.12B

IQV

IQVIA Holdings Inc.

$45.53B

WAT

Waters Corporation

$44.92B

View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About ENDRA Life Sciences Inc. Common Stock

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Visit website →